Tear flow in XXXX recipients.

@entity1 @entity500 @entity229 @entity205 @entity792
PURPOSE: To measure tear flow in renal allograft recipients who received oral @entity205 as immunosuppressive therapy. @entity1 : Control subjects were from the staff of various clinics, dialysis @entity1 were recruited, and one group of kidney transplant recipients took oral @entity205 , whereas another group took @entity500 . Written informed consent was obtained for an institutionally approved protocol. METHODS: A 4-minute Schirmer test with topical anesthetic was performed in both eyes of each @entity1 , and the average score was used in calculations. RESULTS: The tear flow rate was 10.6 mm/4 minutes in the control subjects, 13.6 mm/4 minutes in the dialysis @entity1 , 10.4 mm/4 minutes in kidney transplant recipients taking @entity500 , and 19.0 mm/4 minutes in kidney transplant recipients taking @entity205 . Kidney transplant recipients taking @entity205 had significantly increased tear flow compared with the other three groups (P < 0.05); dialysis @entity1 , kidney transplant recipients taking @entity500 , and control subjects showed statistically indistinguishable tear flow. Within-group comparisons (male versus female, black versus white, and all combinations) showed no statistically significant differences. CONCLUSION: Medications used by dialysis @entity1 or the @entity500 group did not significantly increase tear flow compared with control subjects. The addition of @entity205 (plus @entity229 ) enhanced tear flow in kidney transplant recipients compared with all other groups. Systemic @entity205 appears to increase tear flow even when no lacrimal @entity792 exists.
